320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
The Readout Loud
00:00
Navigating Eli Lilly's Zepbound Pricing Strategy
This chapter analyzes Eli Lilly's recent rollout of discounted vials for its obesity drug, Zepbound, amidst a mixed reception from experts and the public. It also examines the implications of altered pricing strategies and transparency issues in marketing the medication.
Transcript
Play full episode
